Trial · NCT01471665
GSK2190915 Neutrophilic Asthma Study
NCT01471665, Phase 2, Completed, GlaxoSmithKline
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. GSK2190915 Neutrophilic Asthma Study. Trials, record NCT01471665. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01471665
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- GSK2190915 Neutrophilic Asthma Study
- NCT number
- NCT01471665
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 14 participants, actual
- Lead sponsor
- GlaxoSmithKline
- Conditions
- Asthma
- Interventions
- GSK2190915 100mg, Placebo
- First posted
- 2011-11-16
- Last updated
- 2016-11-22
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | The numbers of neutrophils in induced sputum in asthmatic subjects (average of absolute and percentage count on Visit 4 and Visit 5) | 13 - 16 days post treatment with 100mg GSK2190915 or placebo once daily | Pharmacodynamics |
| Secondary | The levels of LTE4 in urine, LTB4-glucuronide in urine and LTB4 in sputum supernatant in asthmatic subjects | Over 13 - 16 days post treatment with 100mg GSK2190915 or placebo once daily | Pharmacodynamics |
| Secondary | The levels of high sensitive C-reactive protein (hsCRP) and other biomarkers (for example IL-17) in blood in asthmatic subjects | Over 13 - 16 days post treatment with 100mg GSK2190915 or placebo once daily | Pharmacodynamics |
| Secondary | Changes in symptoms in asthmatic subjects compared to placebo using the asthma control questionnaire | Over 13 - 16 days post treatment with 100mg GSK2190915 or placebo once daily | Safety and tolerability and efficacy |
| Secondary | Changes in lung function as measured by Forced Expiratory Volume in one second (FEV1) in subjects with asthma | Over 13 - 16 days post treatment with 100mg GSK2190915 or placebo once daily | Safety and tolerability and efficacy |
| Secondary | Plasma concentrations of GSK2190915 following repeated doses in asthmatic subjects | On days 13 - 16 days post treatment with 100mg GSK2190915 or placebo once daily | Pharmacokinetics |
| Secondary | Incidence of treatment emergent adverse events in asthmatic subjects and vital signs, electrocardiograms and safety laboratory parameters in asthmatic subjects | Over 13 - 16 days post treatment with 100mg GSK2190915 or placebo once daily | Safety and tolerability and effiacy |
| Secondary | The levels of biomarkers in sputum supernatant, for example IL-17, IL-8, neutrophil elastase and myeloperoxidase, as samples permit, in asthmatic subjects | Over 13 - 16 days post treatment with 100mg GSK2190915 or placebo once daily | Pharmacodynamics |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 24333186 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01471665
GET https://conductscience.org/api/trials/v1/NCT01471665/registered